FOLR1 Recombinant Monoclonal Antibody

Folate receptor alpha (FOLR1) serves as a critical membrane-bound glycoprotein that mediates cellular uptake of folate, an essential vitamin for DNA synthesis and methylation reactions. This receptor has garnered significant attention in cancer research due to its marked overexpression in epithelial malignancies, particularly ovarian and endometrial carcinomas, while maintaining limited expression in normal tissues. This expression pattern has established FOLR1 as both a diagnostic marker and a promising therapeutic target for antibody-drug conjugates and CAR-T cell therapies.

This recombinant monoclonal antibody, clone 4B11, offers researchers the reproducibility advantages inherent to sequence-defined production. Unlike traditional hybridoma-derived antibodies, recombinant manufacturing ensures consistent performance across lots, eliminating the variability that can compromise longitudinal studies or assay development programs.

Functional ELISA validation demonstrates robust binding activity with cross-species reactivity spanning human and cynomolgus monkey FOLR1. The antibody exhibits high-affinity binding to human FOLR1 with an EC50 of 6.893–7.883 ng/mL, while cynomolgus FOLR1 binding shows even greater sensitivity with an EC50 of 2.900–3.544 ng/mL. This dual-species performance proves particularly valuable for preclinical development workflows where cynomolgus models serve as translational bridges to human applications.

Supplied in a glycerol-based buffer system optimized for long-term stability, this unconjugated human IgG1 format antibody is recommended for ELISA applications at dilutions ranging from 1:5000 to 1:50000. Researchers investigating folate receptor biology, tumor marker expression, or developing FOLR1-targeted therapeutic strategies will find this antibody a reliable tool for their detection and quantification needs.